104 related articles for article (PubMed ID: 38859608)
1. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.
Hirano S; Takahashi H; Nakamura S; Matsuda K; Ishikawa R; Tamura K; Shikano K; Fujita T; Amano H; Nakamura M
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38859608
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
Lin C; Xu G; Gao S; Feng T; Li S
Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
[TBL] [Abstract][Full Text] [Related]
3. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.
Fujita K; Elkington P; Redelman-Sidi G; Kanai O; Yamamoto Y; Imakita T; Okamura M; Nakatani K; Mio T
Cancer Immunol Immunother; 2022 Nov; 71(11):2757-2764. PubMed ID: 35429244
[TBL] [Abstract][Full Text] [Related]
4. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
5. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
[TBL] [Abstract][Full Text] [Related]
6. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
[TBL] [Abstract][Full Text] [Related]
7. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
9. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
Im Y; Lee J; Kim SJ; Koh WJ; Jhun BW; Lee SH
Respir Med; 2020 Jan; 161():105853. PubMed ID: 32056727
[TBL] [Abstract][Full Text] [Related]
10. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
11. Severe eosinophilia and subsequent dermatologic immune-related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab.
Matsumoto T; Kaneko A; Kusakabe Y; Nakayama E; Tanaka A; Yamamoto N; Aihara K; Yamaoka S; Mishima M
Respirol Case Rep; 2022 Oct; 10(10):e01037. PubMed ID: 36176718
[TBL] [Abstract][Full Text] [Related]
12. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Suliman AM; Bek SA; Elkhatim MS; Husain AA; Mismar AY; Eldean MZS; Lengyel Z; Elazzazy S; Rasul KI; Omar NE
Cancer Immunol Immunother; 2021 Apr; 70(4):935-944. PubMed ID: 33070259
[TBL] [Abstract][Full Text] [Related]
14. Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Khalid AB; Calderon G; Jalal SI; Durm GA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1316-1320. PubMed ID: 36509071
[TBL] [Abstract][Full Text] [Related]
15. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.
Nakamura H; Shionoya A; Arihara Y; Hayasaka N; Kubo T; Usami M; Sugita S; Uhara H; Takada K
Front Immunol; 2023; 14():1259071. PubMed ID: 37753079
[TBL] [Abstract][Full Text] [Related]
16. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
17. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
[TBL] [Abstract][Full Text] [Related]
18. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
19. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
